Business
Moderna’s stock has surged 488% in 2020: Is it a buy for 2021?
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
All eyes were on the biotech Moderna (NASDAQ: MRNA) in 2020. It wasn’t quite a popular name in the pharmaceutical space, as it has no approved products on the market yet. But its sudden entry in the COVID-19 vaccine competition grabbed a lot of attention, and it became the second company to win approval in a race with dozens of players. No wonder its stock has surged 488% so far this year, while the S&P 500 has gained 16%.
On Dec. 11, Pfizer (NYSE: PFE) and its German biotech partner BioNTech (NASDAQ: BNTX) became the…
-
Noosa News17 hours agoUnlawful wounding charges, Caloundra – Sunshine Coast
-
General19 hours agoCalifornia worker dead and hundreds arrested after cannabis farm raid
-
General22 hours agoBreaking: Man shot at shopping centre in Sydney's west
-
General21 hours agoWallaroos fall to Black Ferns 37-12 in Wellington Test